Mario Eisenberger
Mario Eisenberger
Professor of Oncology,Johns Hopkins University
Verified email at jhmi.edu
Title
Cited by
Cited by
Year
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ...
New England Journal of Medicine 351 (15), 1502-1512, 2004
64242004
Mortality results from a randomized prostate-cancer screening trial
GL Andriole, ED Crawford, RL Grubb III, SS Buys, D Chia, TR Church, ...
New England Journal of Medicine 360 (13), 1310-1319, 2009
36462009
Natural history of progression after PSA elevation following radical prostatectomy
CR Pound, AW Partin, MA Eisenberger, DW Chan, JD Pearson, PC Walsh
Jama 281 (17), 1591-1597, 1999
34741999
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
22222014
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
21002008
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ...
New England Journal of Medicine 373 (8), 737-746, 2015
20512015
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
ED Crawford, MA Eisenberger, DG McLeod, JT Spaulding, R Benson, ...
New England Journal of Medicine 321 (7), 419-424, 1989
18121989
Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland, EB Humphreys, LA Mangold, M Eisenberger, FJ Dorey, ...
Jama 294 (4), 433-439, 2005
14482005
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock
Journal of Clinical Oncology 26 (2), 242-245, 2008
13032008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock
Journal of Clinical Oncology 26 (2), 242-245, 2008
13032008
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
11041999
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
MA Eisenberger, BA Blumenstein, ED Crawford, G Miller, DG McLeod, ...
New England Journal of Medicine 339 (15), 1036-1042, 1998
10751998
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
JB Nelson, SP Hedican, DJ George, AH Reddi, S Piantadosi, ...
Nature medicine 1 (9), 944-949, 1995
7221995
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
W Liu, S Laitinen, S Khan, M Vihinen, J Kowalski, G Yu, L Chen, ...
Nature medicine 15 (5), 559-565, 2009
6712009
NCCN practice guidelines for cancer-related fatigue.
V Mock, A Atkinson, A Barsevick, D Cella, B Cimprich, C Cleeland, ...
Oncology (Williston Park, NY) 14 (11A), 151-161, 2000
6362000
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
5812015
Cancer-related fatigue, version 2.2015
AM Berger, K Mooney, A Alvarez-Perez, WS Breitbart, KM Carpenter, ...
Journal of the National Comprehensive Cancer Network 13 (8), 1012-1039, 2015
4852015
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ...
Journal of Clinical Oncology 36 (11), 1080, 2018
4762018
Long‐term effects of androgen deprivation therapy in prostate cancer patients
S Basaria, J Lieb, AM Tang, T DeWeese, M Carducci, M Eisenberger, ...
Clinical endocrinology 56 (6), 779-786, 2002
3902002
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis
AJ Armstrong, ES Garrett-Mayer, YCO Yang, R De Wit, IF Tannock, ...
Clinical Cancer Research 13 (21), 6396-6403, 2007
3872007
The system can't perform the operation now. Try again later.
Articles 1–20